Trial Profile
A Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or Hip
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 23 Jun 2019
Price :
$35
*
At a glance
- Drugs Fasinumab (Primary)
- Indications Pain
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 17 Jun 2019 Results published in the Arthritis and Rheumatology
- 22 Dec 2016 Status changed from active, no longer recruiting to completed.
- 17 Oct 2016 According to a Regeneron Pharmaceuticals media release, the company is planning to advance only lower doses in phase 3 program, subject to discussion with FDA and other regulatory authorities.